CardioGenics Holdings Inc
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Yahia Abdul Gawad
- Full Time Employees
- 4
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Address
- 6295 Northam Drive Mississauga ON Canada L4V 1W8
- IPO Date
- Jun 9, 2004
- Website
- cardiogenics.com
- Similar Companies
- Business
- CardioGenics Holdings Inc. engages in the development and commercialization of diagnostic test products targeting the immunoassay segment of the in vitro diagnostics testing market in the United States, Canada, Europe, and internationally; its core offerings include the QL Care Analyzer, a portable, stand-alone, automated point-of-care immunoassay analyzer utilizing proprietary self-metering cartridges for on-site testing; a series of immunoassay tests designed to identify cardiac markers in blood during heart attacks; and paramagnetic beads serving as solid surfaces for heterogeneous immunoassay tests employed by clinical and research laboratories. Founded in 1997 and headquartered at 6295 Northam Drive, Unit 8, Mississauga, Ontario, L4V 1W8, Canada, the company, led by Founder, CEO and Director Dr. Yahia Gawad, focuses on innovative, cost-effective, patent-protected technologies to enhance healthcare professionals' diagnostic capabilities and patient management while reducing costs. Originally known as Jag Media Holdings Inc., it changed its name to CardioGenics Holdings Inc. in 2009; among its earlier strategic moves, it entered an asset purchase agreement in November 2015 to acquire substantially all assets of Ontario-based Plasticap, including manufacturing expertise for plastics to support production of its QL Care Analyzer cartridges and expansion into healthcare plastics, while maintaining Plasticap's client base, with related real property transactions finalized separately.
Company News
CardioGenics (OTCMKTS:CGNH) Stock Price Breaks Above Two Hundred Day Moving Average – Time to Sell?
CardioGenics (OTCMKTS:CGNH) Share Price Breaks Above 200 Day Moving Average – Should You Sell?
CardioGenics (OTCMKTS:CGNH) Shares Cross Above Two Hundred Day Moving Average – Should You Sell?
CardioGenics (OTCMKTS:CGNH) Share Price Crosses Above Two Hundred Day Moving Average – Should You Sell?
CardioGenics (OTCMKTS:CGNH) & Avanos Medical (NYSE:AVNS) Financial Review
CardioGenics (OTCMKTS:CGNH) Share Price Passes Above 200-Day Moving Average – Here’s Why
Comparing CardioGenics (OTCMKTS:CGNH) & LENSAR (NASDAQ:LNSR)
Contrasting DarioHealth (NASDAQ:DRIO) and CardioGenics (OTCMKTS:CGNH)
Head-To-Head Analysis: IDEXX Laboratories (NASDAQ:IDXX) vs. CardioGenics (OTCMKTS:CGNH)
Head-To-Head Contrast: CardioGenics (OTCMKTS:CGNH) versus Nielsen (OTCMKTS:NLSN)